Business Description
Penumbra Inc
NAICS : 339999
SIC : 3841
ISIN : US70975L1070
Description
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.49 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | 11.92 | |||||
| Interest Coverage | 214.98 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 13.9 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.9 | |||||
| 3-Year Book Growth Rate | 20 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 23.59 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 14 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.29 | |||||
| 9-Day RSI | 52.21 | |||||
| 14-Day RSI | 54.05 | |||||
| 6-1 Month Momentum % | -29.75 | |||||
| 12-1 Month Momentum % | -43.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.25 | |||||
| Quick Ratio | 3.77 | |||||
| Cash Ratio | 2.25 | |||||
| Days Inventory | 325.18 | |||||
| Days Sales Outstanding | 65.05 | |||||
| Days Payable | 25.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2 | |||||
| Shareholder Yield % | -0.02 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.51 | |||||
| Operating Margin % | 6.52 | |||||
| Net Margin % | 1.26 | |||||
| FCF Margin % | 9.75 | |||||
| ROE % | 1.25 | |||||
| ROA % | 0.94 | |||||
| ROIC % | -8.09 | |||||
| 3-Year ROIIC % | 18.63 | |||||
| ROC (Joel Greenblatt) % | -1.3 | |||||
| ROCE % | -0.73 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 588.26 | |||||
| Forward PE Ratio | 55.56 | |||||
| PE Ratio without NRI | 91.12 | |||||
| Shiller PE Ratio | 605.53 | |||||
| PS Ratio | 6.91 | |||||
| PB Ratio | 6.69 | |||||
| Price-to-Tangible-Book | 7.86 | |||||
| Price-to-Free-Cash-Flow | 70.9 | |||||
| Price-to-Operating-Cash-Flow | 61.3 | |||||
| EV-to-EBIT | -770.69 | |||||
| EV-to-EBITDA | 398.85 | |||||
| EV-to-Forward-EBITDA | 60.22 | |||||
| EV-to-Revenue | 6.76 | |||||
| EV-to-Forward-Revenue | 5.67 | |||||
| EV-to-FCF | 69.2 | |||||
| Price-to-Projected-FCF | 8.27 | |||||
| Price-to-Graham-Number | 5.65 | |||||
| Price-to-Net-Current-Asset-Value | 13.61 | |||||
| Earnings Yield (Greenblatt) % | -0.13 | |||||
| FCF Yield % | 1.42 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers